Comparison between 1st generation EGFR tyrosine kinase inhibitor (gefitinib) versus 2nd generation (afatinib) in EGFR-mutated non-small cell lung cancers (NSCLC) – real world experience. (June 2021) - Dulloo, Sean; Almusarhed, Manar; Chen, Ryan; Akala, Oyeyemi; Varadhan, Balaji; Chauhan, Meera; Ahmed, Samreen